Serum microRNA expression levels in Turkish patients with Parkinson’s disease

References

• De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Raymick J, Imam S. Neuroprotective and therapeutic strategies against Parkinson’s disease: recent perspectives. Int J Mol Sci. 2016;17(6):904.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• Hallett PJ, Engelender S, Isacson O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease. J Neuroinflamm. 2019;16:153.
   PubMed Web of Science ®Google Scholar
• Burgos K, Malenica I, Metpally R, et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PloS One. 2014;9(5):e94839
   PubMed Web of Science ®Google Scholar
• Danborg PB, Simonsen AH, Waldemar G, et al. The potential of microRNAs as biofluid markers of neurodegenerative diseases-a systematic review. Biomarkers. 2014;19(4):259–268.
   PubMed Web of Science ®Google Scholar
• Basak I, Patil K, Alves G, et al. microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases. Cell Mol Life Sci. 2015;1:17.
   Google Scholar
• Grasso M, Piscopo P, Crestini A, et al. Circulating microRNAs in neurodegenerative diseases. Exp Suppl. 2015;106:151–169.
   PubMedGoogle Scholar
• Mushtaq G, Greig NH, Anwar F, et al. miRNAs as circulating biomarkers for Alzheimer's disease and Parkinson's disease. Med Chem. 2016;12(3):217–225.
   PubMed Web of Science ®Google Scholar
• Leggio L, Vivarelli S, L’Episcopo F, et al. microRNAs in Parkinson’s disease: from pathogenesis to novel diagnostic and therapeutic approaches. Int J Mol Sci. 2017;18(12):2698. 13pii:
   PubMed Web of Science ®Google Scholar
• Martinez B, Peplow PV. MicroRNAs in Parkinson's disease and emerging therapeutic targets. Neural Regen Res. 2017;12(12):1945–1959.
   PubMed Web of Science ®Google Scholar
• Khoo SK, Petillo D, Kang UJ, et al. Plasma-based circulating microRNA biomarkers for Parkinson's disease. J Parkinsons Dis. 2012;2(4):321–331.
   PubMedGoogle Scholar
• Heman-Ackah SM, Hallegger M, Rao MS, et al. RISC in PD: The impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis. Front Mol Neurosci. 2013;6:40.
   PubMed Web of Science ®Google Scholar
• da Silva FC, Iop RDR, Vietta GG, et al. microRNAs involved in Parkinson's disease: a systematic review. Mol Med Rep. 2016;14(5):4015–4022.
   PubMed Web of Science ®Google Scholar
• Batistela MS, Josviak ND, Sulzbach CD, et al. An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's diseases. Int J Neurosci. 2017;127(6):547–558.
   PubMed Web of Science ®Google Scholar
• Emamzadeh FN, Surguchov A. Parkinson's disease: biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612.
   PubMed Web of Science ®Google Scholar
• Kehl T, Backes C, Kern F, et al. About miRNAs, miRNA seeds, target genes and target pathways. Oncotarget. 2017;8(63):107167–107175.
   PubMedGoogle Scholar
• Wang Y, Yang Z, Le W. Tiny but mighty: promising roles of microRNAs in the diagnosis and treatment of Parkinson's disease. Neurosci Bull. 2017;33(5):543–551.
   PubMed Web of Science ®Google Scholar
• Botta-Orfila T, Morató X, Compta Y, et al. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease. J Neurosci Res. 2014;92(8):1071–1077.
   PubMed Web of Science ®Google Scholar
• Serafin A, Foco L, Blankenburg H, et al. Identification of a set of endogenous reference genes for miRNA expression studies in Parkinson's disease blood samples. BMC Res Notes. 2014;7:715.
   PubMedGoogle Scholar
• Cao XY, Lu JM, Zhao ZQ, et al. MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles. Neurosci Lett. 2017;644:94–99.
   PubMed Web of Science ®Google Scholar
• Chou CH, Chang NW, Shrestha S, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 2016;44(D1):D239–247.
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–874.
   PubMed Web of Science ®Google Scholar
• Salta E, De Strooper B. Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurol. 2012;11(2):189–200.
   PubMed Web of Science ®Google Scholar
• Stoicea N, Du A, Lakis DC, et al. The miRNA journey from theory to practice as a CNS biomarker. Front Genet. 2016;7:11.
   PubMed Web of Science ®Google Scholar
• Quinlan S, Kenny A, Medina M, et al. MicroRNAs in neurodegenerative diseases. Int Rev Cell Mol Biol. 2017;334:309–343.
   PubMed Web of Science ®Google Scholar
• Mouradian MM. MicroRNAs in Parkinson's disease. Neurobiol Dis. 2012;46(2):279–284.
   PubMed Web of Science ®Google Scholar
• Majidinia M, Mihanfar A, Rahbarghazi R, et al. The roles of non-coding RNAs in Parkinson's disease. Mol Biol Rep. 2016;43(11):1193–1204.
   PubMed Web of Science ®Google Scholar
• Teixeira dos Santos MC, Bell R, da Costa AN. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting. Bioanalysis. 2016;8(23):2497–2518.
   PubMed Web of Science ®Google Scholar
• Singh A, Sen D. MicroRNAs in Parkinson's disease. Exp Brain Res. 2017;235(8):2359–2374.
   PubMed Web of Science ®Google Scholar
• Chi J, Xie Q, Jia J, et al. Integrated analysis and identification of novel biomarkers in Parkinson's Disease. Front Aging Neurosci. 2018;10:178.
   PubMed Web of Science ®Google Scholar
• Tan C, Liu X, Chen J. Microarray analysis of the molecular mechanism involved in parkinson’s disease. Parkinsons Dis. 2018; 2018:1590465–1590462.
   PubMed Web of Science ®Google Scholar
• Qiu L, Zhang W, Tan EK, et al. Deciphering the function and regulation of microRNAs in Alzheimer's disease and Parkinson's disease. ACS Chem Neurosci. 2014;5(10):884–894.
   PubMed Web of Science ®Google Scholar
• Chmielarz P, Konovalova J, Najam SS, et al. Dicer and microRNAs protect adult dopamine neurons. Cell Death Dis. 2017;8(5):e2813.
   PubMed Web of Science ®Google Scholar
• Rassu M, Del Giudice MG, Sanna S, et al. Role of LRRK2 in the regulation of dopamine receptor trafficking. PLoS ONE. 2017;12(6):e0179082.
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–39.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591–1601.
   PubMed Web of Science ®Google Scholar
• Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649–2653.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force report on the hoehn and yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020
   PubMed Web of Science ®Google Scholar
• Fahn BS, Elton R, M.o.t.U.D. Committee. Unified Parkinson’s disease rating scale. In: Recent developments in Parkinson’s disease. Florham Park, NY: Macmillan Health Care Information; 1987; p. 153–e64.
   Google Scholar
• Gui Y, Liu H, Zhang L, et al. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 2015;6(35):37043–37053.
   PubMedGoogle Scholar
• Chahine LM, Stern MB. Diagnostic markers for Parkinson's disease. Curr Opin Neurol. 2011;24(4):309–317.
   PubMed Web of Science ®Google Scholar
• He R, Yan X, Guo J, et al. Recent advances in biomarkers for Parkinson's disease. Front Aging Neurosci. 2018;10:305.
   PubMed Web of Science ®Google Scholar
• Khodadadian A, Hemmati-Dinarvand M, Kalantary-Charvadeh A, et al. Candidate biomarkers for Parkinson's disease. Biomed Pharmacother. 2018;104:699–704.
   PubMed Web of Science ®Google Scholar
• Arshad AR, Sulaiman SA, Saperi AA, et al. MicroRNAs and target genes as biomarkers for the diagnosis of early onset of Parkinson disease. Front Mol Neurosci. 2017;10:352.
   PubMed Web of Science ®Google Scholar
• Serafin A, Foco L, Zanigni S, et al. Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD. Neurology. 2015;84(7):645–649.
   PubMed Web of Science ®Google Scholar
• Goh SY, Chao YX, Dheen ST, et al. Role of microRNAs in Parkinson’s disease. Int J Mol Sci. 2019;20(22):5649.
   PubMed Web of Science ®Google Scholar
• Schulz J, Takousis P, Wohlers I, et al. Meta-analyses identify differentially expressed micrornas in Parkinson's disease. Ann Neurol. 2019;85(6):835–851.
   PubMed Web of Science ®Google Scholar
• Mooney C, Raoof R, El-Naggar H, et al. High throughput qPCR expression profiling of circulating microRNAs reveals minimal sex- and sample timing-related variation in plasma of healthy volunteers. PloS ONE. 2015;10(12):e0145316.
   PubMed Web of Science ®Google Scholar
• Ma W, Li Y, Wang C, et al. Serum miR-221 serves as a biomarker for Parkinson's disease. Cell Biochem Funct. 2016;34(7):511–515.
   PubMed Web of Science ®Google Scholar
• Bai X, Tang Y, Yu M, et al. Downregulation of blood serum microRNA 29 family in patients with Parkinson's disease. Sci Rep. 2017;7(1):5411.
   PubMed Web of Science ®Google Scholar
• Martins M, Rosa A, Guedes LC, et al. Convergence of miRNA expression profiling, a-synuclein interacton and GWAS in Parkinson’s disease. PLoS ONE. 2011;6(10):e25443.
   PubMed Web of Science ®Google Scholar
• Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsonĭs disease. J Biotechnol. 2011;152(3):96–101.
   PubMed Web of Science ®Google Scholar
• Ding H, Huang Z, Chen M, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. Parkinsonism Relat Disord. 2016;22:68–73.
   PubMed Web of Science ®Google Scholar
• Ragonese P, D'Amelio M, Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann N Y Acad Sci. 2006;1089:373–382.
   PubMed Web of Science ®Google Scholar
• Dong H, Wang C, Lu S, et al. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease. Biomarkers. 2016;21(2):129–137.
   PubMed Web of Science ®Google Scholar